Skip to main content
Qingdao Baheal Medical INC. logo

Qingdao Baheal Medical INC. — Investor Relations & Filings

Ticker · 301015 ISIN · CNE100004LR8 LEI · 300300TEZL228WDQ5W83 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 790 across all filing types
Latest filing 2026-06-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301015

About Qingdao Baheal Medical INC.

https://www.baheal.cn

Qingdao Baheal Medical INC. operates as a professional health brand commercialization platform, specializing in the marketing, distribution, and management of pharmaceuticals, medical devices, and health products. The company provides end-to-end commercialization services, including brand positioning, academic promotion, and supply chain management. By utilizing a data-driven approach and an extensive network encompassing retail pharmacies and medical institutions, Baheal facilitates market penetration for both domestic and international healthcare brands. Its core business model focuses on optimizing the pharmaceutical value chain through digital healthcare solutions and professional brand operations, ensuring efficient delivery of medical products to the end-user market.

Recent filings

Filing Released Lang Actions
关于关联方向全资子公司增资暨关联交易的进展公告
Capital/Financing Update Classification · 85% confidence The document is an official announcement by Qingdao Baiyang Pharmaceutical Co., Ltd. regarding the progress of a related-party capital injection into its wholly owned subsidiary. This involves a financing activity and change in capital structure (the subsidiary’s capital increase). It is not an AGM material, earnings release, or a full financial report, but rather an update on a financing/capital transaction. Therefore it best fits the “Capital/Financing Update” category (CAP).
2026-06-05 Chinese
关于百洋转债恢复转股的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement regarding the resumption of conversion of the company’s convertible bonds (“百洋转债”), specifying bond codes, suspension and resumption dates. This concerns a change in the status of a financing instrument and impacts the company’s capital structure. It is not a report publication or management discussion, nor a dividend or share buyback notice. It best fits Capital/Financing Update (CAP).
2026-05-28 Chinese
关于调整百洋转债转股价格的公告
Capital/Financing Update Classification · 89% confidence The document is an official corporate announcement by Qingdao Baiyang Pharmaceutical regarding an adjustment to the conversion price of its outstanding convertible bonds (“百洋转债”). It details the old and new conversion prices, the effective date, the regulatory basis, formulae for adjustments, and the trigger (2025 cash dividend). This is not an interim or annual financial report, nor an earnings release or dividend notice by itself, but rather pertains to a change in a financing instrument’s terms—namely, a convertible bond conversion price adjustment, which is a capital structure change. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-22 Chinese
2025年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled “2025年度权益分派实施公告” and details the company’s approved 2025 profit distribution plan, including cash dividend per 10 shares, record date, payment date, dividend amounts, tax handling, and related parameters. This is a standard notice announcing the dividend amount and timing to shareholders. Therefore, it fits the “Notice of Dividend Amount” category.
2026-05-22 Chinese
关于实施2025年度权益分派期间百洋转债暂停转股的公告
Capital/Financing Update Classification · 75% confidence The document is an official corporate announcement regarding the temporary suspension of conversion rights for the company’s convertible bonds during the 2025 dividend distribution period. It does not contain financial statements or earnings data, nor is it a proxy, dividend notice or regulatory certification. Instead, it updates terms of a financing instrument (the convertible bond), which falls under capital/financing updates. Therefore, it should be classified as a Capital/Financing Update (CAP).
2026-05-20 Chinese
北京市天元律师事务所关于青岛百洋医药股份有限公司2025年年度股东会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2025 Annual General Meeting (AGM) of Qingdao Baiyang Pharmaceutical Co., Ltd. It details the meeting date, voting methods (onsite and online), shareholder attendance, and the approval of various proposals including the board's work report, profit distribution, guarantees, credit applications, and remuneration schemes. The document is not the AGM materials or presentations themselves but a legal opinion validating the AGM process and results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and confirms the legality of the AGM procedures. The document length is over 5,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2026-05-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.